{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.93","upperLimit":"21.39","value":"17.48"},{"groupId":"OG001","lowerLimit":"6.93","upperLimit":"21.75","value":"12.02"},{"groupId":"OG002","lowerLimit":"6.60","upperLimit":"22.67","value":"8.33"},{"groupId":"OG003","lowerLimit":"2.76","upperLimit":"8.34","value":"3.48"},{"comment":"Due to small number of events, estimate (upper limit of 95% confidence interval) from Kaplan-Meier survival curves could not derive.","groupId":"OG004","lowerLimit":"4.04","upperLimit":"NA","value":"21.42"},{"comment":"Due to small number of events, estimate (upper limit of 95% confidence interval) from Kaplan-Meier survival curves could not derive.","groupId":"OG007","lowerLimit":"6.80","upperLimit":"NA","value":"8.41"},{"comment":"Due to small number of events, estimates (median and upper limit of 95% confidence interval) from Kaplan-Meier survival curves could not derive.","groupId":"OG008","lowerLimit":"2.63","upperLimit":"NA","value":"NA"},{"comment":"Due to small number of events, estimate (upper limit of 95% confidence interval) from Kaplan-Meier survival curves could not derive.","groupId":"OG009","lowerLimit":"11.07","upperLimit":"NA","value":"15.21"},{"comment":"As per planned analysis, data was analyzed in form of graph and no descriptive analysis was performed.","groupId":"OG010","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Due to small number of events, estimate (upper limit of 95% confidence interval) from Kaplan-Meier survival curves could not derive.","groupId":"OG011","lowerLimit":"4.17","upperLimit":"NA","value":"10.38"},{"comment":"Due to small number of events, estimate (upper limit of 95% confidence interval) from Kaplan-Meier survival curves could not derive.","groupId":"OG012","lowerLimit":"2.79","upperLimit":"NA","value":"9.94"},{"comment":"Due to small number of events, estimates (median and upper limit of 95% confidence interval) from Kaplan-Meier survival curves could not derive.","groupId":"OG013","lowerLimit":"6.93","upperLimit":"NA","value":"NA"},{"comment":"Due to small number of events, estimates (median and upper limit of 95% confidence interval) from Kaplan-Meier survival curves could not derive.","groupId":"OG014","lowerLimit":"2.69","upperLimit":"NA","value":"NA"},{"comment":"As per planned analysis, data was analyzed in form of graph and no descriptive analysis was performed.","groupId":"OG015","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Due to small number of events, estimates (median and upper limit of 95% confidence interval) from Kaplan-Meier survival curves could not derive.","groupId":"OG016","lowerLimit":"2.79","upperLimit":"NA","value":"NA"},{"comment":"Due to small number of events, estimates (median and upper limit of 95% confidence interval) from Kaplan-Meier survival curves could not derive.","groupId":"OG017","lowerLimit":"8.31","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"11"},{"groupId":"OG009","value":"5"},{"groupId":"OG010","value":"6"},{"groupId":"OG011","value":"12"},{"groupId":"OG012","value":"10"},{"groupId":"OG013","value":"2"},{"groupId":"OG014","value":"7"},{"groupId":"OG015","value":"31"},{"groupId":"OG016","value":"8"},{"groupId":"OG017","value":"20"}],"units":"Participants"}],"description":"Duration of response according to RECIST 1.1, per investigator assessment was calculated for each participant with a confirmed response (complete response \\[CR\\] or partial response \\[PR\\]) as the time from the first observation of response to the first observation of documented disease progression (or death within 12 weeks of the last tumor assessment). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. Results were calculated based on Kaplan-Meier estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with non-small cell lung cancer (NSCLC), who had progressed after 1 line of platinum-containing doublet chemotherapy received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG000","title":"Primary Expansion Cohort: NSCLC, Post-platinum Doublet"},{"description":"Participants with non-small cell lung cancer (NSCLC), first line received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG001","title":"Primary Expansion Cohort: NSCLC, First Line"},{"description":"Participants with metastatic breast cancer received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG002","title":"Primary Expansion Cohort: Metastatic Breast Cancer"},{"description":"Participants with gastric and gastroesophageal cancer who progressed on or after first-line chemotherapy received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG003","title":"Primary Expansion Cohort: GC/GEJC Progressed"},{"description":"Participants with gastric and gastroesophageal cancer who non-progressed on or after first-line chemotherapy received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG004","title":"Primary Expansion Cohort: GC/GEJC Non Progressed"},{"description":"Participants with colorectal cancer received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG005","title":"Secondary Expansion Cohort: Colorectal Cancer"},{"description":"Participants with castrate-resistant prostate cancer received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG006","title":"Secondary Expansion Cohort: Castrate-resistant Prostate Cancer"},{"description":"Participants with adrenocortical carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG007","title":"Secondary Expansion Cohort: Adrenocortical Carcinoma"},{"description":"Participants with melanoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG008","title":"Secondary Expansion Cohort: Melanoma"},{"description":"Participants with mesothelioma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG009","title":"Secondary Expansion Cohort: Mesothelioma"},{"description":"Participants with urothelial carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG010","title":"Secondary Expansion Cohort: Urothelial Carcinoma"},{"description":"Participants with ovarian carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG011","title":"Secondary Expansion Cohort: Ovarian Cancer"},{"description":"Participants with Renal cell carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks as a first-line therapy in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG012","title":"Secondary Expansion Cohort: Renal Cell Carcinoma (First Line)"},{"description":"Participants with Renal cell carcinoma who failed 1 prior systemic first-line regimen received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks as a second line treatment in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG013","title":"Secondary Expansion Cohort: Renal Cell Carcinoma (Second Line)"},{"description":"Participants with ovarian carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG014","title":"Efficacy Expansion Cohort: Ovarian Cancer"},{"description":"Participants with urothelial carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG015","title":"Efficacy Expansion Cohort: Urothelial Carcinoma"},{"description":"Participants with gastric (GC) and gastroesophageal junction cancer (GEJC) who have failed both a first-line chemotherapy regimen and subsequent ramucirumab therapy, received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks as a third-line treatment in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG016","title":"Efficacy Expansion Cohort: GC/GEJC, Third Line"},{"description":"Participants with head and neck squamous cell carcinoma (HNSCC) received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG017","title":"Efficacy Expansion Cohort: HNSCC"}],"paramType":"MEDIAN","populationDescription":"FAS included all participants who have received at least 1 dose of study treatment. Data for this outcome measure is reported for the participants with Complete or Partial response.","reportingStatus":"POSTED","timeFrame":"Dose Expansion: Baseline up to Day 2023","title":"Dose Expansion Cohort: Duration of Response According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Per Investigator Assessment","type":"SECONDARY","unitOfMeasure":"Months"}